原始来源记录
决策级顶线结果
IDEAYA: OptimUM-02 2/3期 darovasertib + crizotinib 达到PFS终点
OptimUM-02试验达到主要终点，显示疾病进展风险降低58%（HR 0.42），中位PFS为6.9个月，而研究者选择治疗组为3.1个月。ORR分别为37.1%和5.8%，darovasertib组有5例完全缓解。IDEAYA计划基于这些数据在2026年下半年提交NDA。
关键事实
- 申报时间
- 2026年4月13日 10:05
- 事件
- 顶线结果
- 方向
- 积极
- 来源
- SEC 8-K
- 可信度
- 有来源
- HR
- 0.42
- P值
- <0.0001
- 中位PFS
- 6.9 vs 3.1个月
来源摘录
8-K false 0001676725 0001676725 2026-04-13 2026-04-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2026 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number) 5000 Shoreline Court , Suite 300 South San Francisco , California 94080 (Address of principal executive offices, including Zip Code) Registrant’s telephone number, including area code: (650) 443-6209 Check the appropriate box below if the Form 8-K filing is intended to simultaneous